Last reviewed · How we verify
PF-06838435/ fidanacogene elaparvovec (pf-06838435-fidanacogene-elaparvovec)
PF-06838435/ fidanacogene elaparvovec (generic name: pf-06838435-fidanacogene-elaparvovec) is a Gene therapy drug developed by Pfizer Inc.. It is currently in Phase 3 development.
At a glance
| Generic name | pf-06838435-fidanacogene-elaparvovec |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Gene therapy |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06838435/ fidanacogene elaparvovec CI brief — competitive landscape report
- PF-06838435/ fidanacogene elaparvovec updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about PF-06838435/ fidanacogene elaparvovec
What is PF-06838435/ fidanacogene elaparvovec?
PF-06838435/ fidanacogene elaparvovec (pf-06838435-fidanacogene-elaparvovec) is a Gene therapy drug developed by Pfizer Inc..
Who makes PF-06838435/ fidanacogene elaparvovec?
PF-06838435/ fidanacogene elaparvovec is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of PF-06838435/ fidanacogene elaparvovec?
pf-06838435-fidanacogene-elaparvovec is the generic (nonproprietary) name of PF-06838435/ fidanacogene elaparvovec.
What development phase is PF-06838435/ fidanacogene elaparvovec in?
PF-06838435/ fidanacogene elaparvovec is in Phase 3.